EMA Authorised: Kapruvia (difelikefalin) — Vifor Fresenius Medical Care Renal Pharma France

View source ↗

Summary

The EMA authorised Kapruvia (difelikefalin) for chronic kidney disease–associated pruritus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease-associated Pruritus

Drugs mentioned

• Kapruvia (difelikefalin)

Snippet

Status: Authorised. Therapeutic area: Pruritus. MAH: Vifor Fresenius Medical Care Renal Pharma France. Decision date: 06/01/2026